# OnCo record uterine-sarcoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/uterine-sarcoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "uterine-sarcoma" ;
  schema:name "Uterine sarcoma"@en ;
  schema:alternateName "Leiomyosarcoma of the uterus"@en, "Endometrial stromal sarcoma"@en, "Undifferentiated uterine sarcoma"@en, "Uterine LMS"@en, "ESS"@en ;
  schema:description "Uterine sarcomas are rare cancers of the muscle and supporting tissue of the womb, distinct from the far commoner endometrial cancer. Removing the uterus intact is the main treatment and is followed by observation for stage I disease; low-grade stromal sarcomas respond to hormone-blocking pills, while advanced leiomyosarcoma is treated with doxorubicin and trabectedin."@en ;
  schema:url <https://onco.cc/cancers/uterine-sarcoma/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Uterine_sarcoma> ;
  schema:citation <https://www.cancer.gov/types/uterine/patient/uterine-sarcoma-treatment-pdq>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1473>, <https://doi.org/10.1016/S1470-2045(22)00380-1>, <https://doi.org/10.1016/S1470-2045(17)30622-8> ;
  onco:tag "nci-coverage", "rare", "gynaecologic", "sarcoma" ;
  onco:related <https://onco.cc/cancers/leiomyosarcoma/>, <https://onco.cc/cancers/retroperitoneal-sarcoma/>, <https://onco.cc/cancers/liposarcoma/>, <https://onco.cc/cancers/pecoma/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/endocrine-therapy/>, <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/mri/> ;
  onco:targets <https://onco.cc/targets/estrogen-receptor/>, <https://onco.cc/targets/ntrk/>, <https://onco.cc/targets/alk/>, <https://onco.cc/targets/parp/> ;
  onco:drugs <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/trabectedin/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/docetaxel/>, <https://onco.cc/drugs/pazopanib/>, <https://onco.cc/drugs/eribulin/>, <https://onco.cc/drugs/letrozole/>, <https://onco.cc/drugs/megestrol-progestins/>, <https://onco.cc/drugs/larotrectinib/>, <https://onco.cc/drugs/entrectinib/>, <https://onco.cc/drugs/crizotinib/> ;
  onco:pathways <https://onco.cc/pathways/er-signaling/>, <https://onco.cc/pathways/homologous-recombination-repair/> ;
  onco:terms <https://onco.cc/terms/hysterectomy/>, <https://onco.cc/terms/rare-cancers/> ;
  onco:trials <https://onco.cc/trials/nct06088290/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-rare-cancers/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-seddon-lancet-oncol/> ;
  onco:pipeline <https://onco.cc/drugs/trabectedin/>, <https://onco.cc/drugs/larotrectinib/>, <https://onco.cc/drugs/pazopanib/> ;
  onco:standardOfCare <https://onco.cc/terms/hysterectomy/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/trabectedin/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/docetaxel/>, <https://onco.cc/drugs/pazopanib/>, <https://onco.cc/drugs/eribulin/>, <https://onco.cc/drugs/letrozole/>, <https://onco.cc/drugs/megestrol-progestins/>, <https://onco.cc/technologies/endocrine-therapy/>, <https://onco.cc/drugs/larotrectinib/>, <https://onco.cc/drugs/entrectinib/>, <https://onco.cc/drugs/crizotinib/>, <https://onco.cc/drugs/imatinib/> .